Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cadrenal Therapeutics, Inc. ( (CVKD) ) just unveiled an announcement.
On February 4, 2025, Cadrenal Therapeutics, Inc. appointed Dr. James J. Ferguson as its new Chief Medical Officer, effective February 5, 2025, following the mutually amicable departure of Dr. Douglas Losordo. Dr. Ferguson, with extensive experience in cardiovascular medicine, will lead the late-stage clinical development of tecarfarin, including a pivotal Phase 3 trial for LVAD patients. This leadership transition is expected to strengthen Cadrenal’s efforts in addressing unmet medical needs associated with standard warfarin therapy and enhance its pipeline of specialized cardiovascular treatments.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company that focuses on developing specialized cardiovascular therapies. The company is advancing tecarfarin, a new Vitamin K antagonist, aimed at providing a safer alternative to warfarin for patients with implanted cardiac devices, particularly those with rare cardiovascular conditions requiring life-long anticoagulation therapy.
YTD Price Performance: 23.23%
Average Trading Volume: 63,315
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $34.05M
Find detailed analytics on CVKD stock on TipRanks’ Stock Analysis page.